Providing long-acting (LA) antiretroviral therapy (ART) to breastfeeding women with HIV who face adherence challenges may be ...

When it came to innovations in biotech, there was a clear winner: lenacapavir, a drug that was found to prevent HIV infections in 100% of the women and girls who received it in a clinical trial.

Discover why starting HIV treatment promptly preserves immune function, prevents transmission, improves quality of life and ...

Data from a very early-phase trial shows that the drug is safe and remains in the body for up to 56 weeks. From two ...

Researchers assessed epidemiologic trends of incident hepatitis C virus infection among patients with HIV infection engaged in care in the US.

Olga Rivera Ballesteros from the Center for Infectious Medicine (CIM) at the Department of Medicine, Huddinge (MedH) is ...

Two more people have been potentially cured of HIV after receiving stem cell transplants to treat blood cancer or bone marrow ...

Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

An annual shot to protect against HIV infection has successfully passed an early safety trial, according to research ...

HIV/AIDS continues to disproportionately affect Black Americans, despite overall progress in reducing infection rates.